PLSE — Pulse Biosciences, Inc. stock price, charts and financials

QT64Pulse Biosciences, Inc.

Pulse Biosciences, Inc. (NASDAQ: PLSE) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
41.99
-0.42-0.99%
OverviewShort InterestFilings
PLSEQT64Pulse Biosciences, Inc.·NASDAQ
41.99-0.99%
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
XRAY-2.76%$11.79ATRC+1.01%$41.81NVST+0.14%$28.19ICUI-0.12%$184.34LMAT-0.29%$81.21BLFS-0.71%$34.41MMSI+1.44%$90.32STVN+0.44%$20.36
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand69.21MPerf Week20.72%
Market Cap2.94BForward P/E-EPS next Y-1.20Insider Trans2.27%Shs Float12.77MPerf Month55.69%
Enterprise Value2.84BPEG3.66EPS next Q-Inst Own-Short Float4.18%Perf Quarter116.49%
Income-80.13MP/S-EPS this Y-Inst Trans-Short Ratio8.58Perf Half Y209.79%
Sales1.19MP/B29.50EPS next Y-4.96%ROA-69.27%Short Interest2.89MPerf YTD208.89%
Book/sh-P/C-EPS next 5Y-ROE-94.42%52W High45.44 -7.60%Perf Year176.47%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-78.14%52W Low12.44 237.66%Perf 3Y485.77%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin-21.60%Volatility8.60% 7.96%Perf 5Y106.88%
Dividend TTM-EV/Sales-EPS Y/Y TTM-19.57%Oper. Margin-7007.76%ATR (14)2.64Perf 10Y798.52%
Dividend Ex-Date-Quick Ratio9.61Sales Y/Y TTM-Profit Margin-6755.78%RSI (14)79.21Recom2.50
Dividend Gr. 3/5Y-Current Ratio9.63EPS Q/Q-58.82%SMA2029.68%Beta1.57Target Price33.50
Payout0.00%Debt/Eq0.07Sales Q/Q-SMA5046.70%Rel Volume1.92Prev Close42.41
Employees116LT Debt/Eq0.07EarningsNov 16SMA200102.97%Avg Volume381.84KPrice41.99
IPO DateMay 18, 2016Option/ShortYes / YesEPS/Sales Surpr.0.00% 60.00%Net Debt/EBITDA1.19Volume734,090Change-0.99%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-28-26ReiteratedOppenheimer$30 → $35
Jun-04-26InitiatedCanaccordBuy$32
Feb-20-26ReiteratedOppenheimer$22 → $30
Feb-06-26ReiteratedMizuho Securities$25 → $30
Jan-30-26InitiatedMizuhoOutperform$25
Sep-21-22DowngradeMaxim GroupBuy → Hold
May-13-22DowngradeHC Wainwright & Co.Buy → Neutral
May-12-20UpgradeH.C. WainwrightNeutral → Buy
Feb-14-20DowngradeH.C. WainwrightBuy → Neutral
Latest News
Aug-07-26
Aug-07-2605:44AM
Pulse Biosciences, Inc. (PLSE) Q2 2026 Earnings Call Transcriptseekingalpha.com
04:05AM
Pulse Biosciences Q2 Earnings Call Highlightsmarketbeat.com
Aug-06-26
Aug-06-2608:13PM
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimateszacks.com
04:06PM
Pulse Biosciences Q2 EPS $(0.36), Inline, Sales $434.000K Miss $533.333K EstimateBenzinga
04:05PM
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Resultsbusinesswire.com
Jul-30-26
Jul-30-2604:05PM
Pulse Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conferencebusinesswire.com
Jul-29-26
Jul-29-2607:00AM
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Studybusinesswire.com
Jul-21-26
Jul-21-2604:05PM
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026businesswire.com
Jul-15-26
Jul-15-2604:05PM
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com
Jun-26-26
Jun-26-2610:18AM
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On FridayBenzinga
Jun-10-26
Jun-10-2606:12PM
Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
Company

Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue
000——————
Cost of Goods Sold Incl. D&A201——————
Gross Profit-10-1——————
Selling, General and Administrative Excl. Other322416——————
Research and Development453228——————
Other Operating Expense-10-2——————
Operating Income-77-56-44——————
Interest Expense001——————
Unusual Expense
—————————
Non-Operating Income (Expense)432——————
Net Income Before Taxes-73-54-42——————
Income Taxes
000——————
Consolidated Net Income-73-54-42——————
Net Income From Continuing Operations-73-54-42——————
Net Income-73-54-42——————
EPS (Recurring)-1.08-0.92-0.88——————
EPS (Basic, Before Extraordinaries)-1.08-0.92-0.88——————
EPS (Diluted)-1.08-0.92-0.88——————
EBITDA-72-52-40——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding675848——————
Market Capitalization9201,010588——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$46.87$37.20$27.53$17.87$8.20● Close Price0.00M6.65M13.30M19.94M26.59MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
DUGGAN ROBERT Wdirector, 10 percent owner:May 11 '26Buy19.691,320,46625,999,97648,370,047May 15
LAVIOLETTE PAUL AChief Executive OfficerMay 11 '26Buy19.6930,000590,70015,846May 11
Danahy Kevin PatrickChief Commercial OfficerFeb 18 '26Sale23.645,000118,20043,298Feb 23
Danahy Kevin PatrickChief Commercial OfficerFeb 18 '26Option Exercise1.535,0007,65048,298Feb 23
Danahy Kevin PatrickChief Commercial OfficerFeb 17 '26Sale23.6320,000472,60043,298Feb 17
Danahy Kevin PatrickChief Commercial OfficerFeb 17 '26Option Exercise1.5320,00030,60063,298Feb 17
Danahy Kevin PatrickChief Commercial OfficerFeb 13 '26Sale23.5320,000470,60043,298Feb 17
Danahy Kevin PatrickChief Commercial OfficerFeb 13 '26Option Exercise1.5320,00030,600325,000Feb 17
Danahy Kevin PatrickChief Commercial OfficerFeb 12 '26Option Exercise1.5320,00030,600345,000Feb 17
Danahy Kevin PatrickChief Commercial OfficerFeb 12 '26Sale23.3720,000467,40043,298Feb 17
Danahy Kevin PatrickChief Commercial OfficerFeb 11 '26Sale25.2020,000504,00043,298Feb 11
Danahy Kevin PatrickChief Commercial OfficerFeb 11 '26Option Exercise1.5320,00030,60063,298Feb 11
Danahy Kevin PatrickChief Commercial OfficerFeb 10 '26Sale23.5220,000470,40043,298Feb 11
Danahy Kevin PatrickChief Commercial OfficerFeb 10 '26Option Exercise1.5320,00030,600385,000Feb 11
Danahy Kevin PatrickChief Commercial OfficerFeb 09 '26Option Exercise1.5320,00030,600405,000Feb 11
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.